2024 Rome, Italy

I-01 Martina Liebich
Modelling of Dexamethasone in Paediatric Leukaemia Patients using a Population Pharmacokinetic Approach
Wednesday 10:30-12:00
I-02 Klaus Lindauer
Model Simplification
Wednesday 10:30-12:00
I-03 Dan Liu
Application of Global Sensitivity Analysis Methods to Determine the most Influential Parameters of a Minimal PBPK Model of Quinidine
Wednesday 10:30-12:00
I-04 Rocio Lledo
PK/PD modelling of an anti-FcRn mAb to optimise FIM design - translation from cyno to human
Wednesday 10:30-12:00
I-05 Florence Loingeville
Using Hamiltonian Monte-Carlo to design longitudinal count studies accounting for parameter and model uncertainties
Wednesday 10:30-12:00
I-06 Amelia Deitchman
Tigecycline-Tetracycline Combination Modeling against Pseudomonas aeruginosa: Application of the General Pharmacodynamic Interaction Term in Various Interaction Models
Wednesday 10:30-12:00
I-07 Dominik Lott
Tolerance modeling: effects of the selective S1P1 receptor modulator ponesimod on heart rate
Wednesday 10:30-12:00
I-08 Rubin Lubomirov
Population pharmacokinetic-based interspecies allometric scaling and prediction of first-in-human (FIH) pharmacokinetics of a new anticancer agent
Wednesday 10:30-12:00
I-09 Inga Ludwig
Correlative analysis of response to treatment and biomarker levels in a setting with a time-to-event efficacy outcome and sparse biomarker data
Wednesday 10:30-12:00
I-10 John C Lukas
Order in patch absorption rates?
Wednesday 10:30-12:00
I-11 Sreenath M Krishnan
Influence of the number of tumor size measurements on model-derived tumor size metrics and prediction of survival
Wednesday 10:30-12:00
I-12 Lei Ma
Dupilumab dose selection for a phase 3 study in asthma patients: pharmacokinetic/pharmacodynamic (PK/PD) modelling and clinical trial simulation
Wednesday 10:30-12:00
I-13 Vincent Madelain
Modeling viral kinetics predicts a rapid establishment of the cytotoxic immune response targeting distinct infected cell compartments in SIV controller macaques (ANRS SIC study)
Wednesday 10:30-12:00
I-14 Paolo Magni
Execution of complex Bayesian workflows with the DDMoRe Interoperability Framework: a case study in the diabetes area
Wednesday 10:30-12:00
I-15 Corinna Maier
Robust parameter estimation for dynamical systems from outlier-corrupted data
Wednesday 10:30-12:00
I-16 Victor Mangas-Sanjuan
Semi-mechanistic Pharmacodynamic model of complex receptor-hormone dynamics
Wednesday 10:30-12:00
I-17 Ben Margetts
Modelling Cytomegalovirus Growth Kinetics in Immunocompromised Children
Wednesday 10:30-12:00
I-18 Dimitris Maris
Asymptotic Analysis on a TMDD model: Control of the process
Wednesday 10:30-12:00
I-19 Emma Martin
Using mixed effects modelling improves detection of drug-gene interactions in mouse trials
Wednesday 10:30-12:00
I-20 Paolo Mazzei
Translational model-based approach to assist the dose-range selection of an antibody-drug conjugate entering Phase I
Wednesday 10:30-12:00
I-21 Nicola Melillo
Multiscale mechanistic models in Systems Pharmacology: development of a model describing Atorvastatin pharmacokinetics through integration of metabolic network in Physiologically Based Pharmacokinetic models.
Wednesday 10:30-12:00
I-22 Sandrine Micallef
Evaluation of tumor kinetics metrics as early endpoint to support decision making in early drug development
Wednesday 10:30-12:00
I-23 Joske Millecam
A new approach in pediatric drug design: the development of a pediatric pig model. Part II: The maturation of hepatic cytochrome P450 enzymes using enzyme activity and proteomics
Wednesday 10:30-12:00
I-24 Jonathan Mochel
One Health: Translational and Reverse Translational Modeling of Inflammatory Bowel Disease using an advanced Boolean Network
Wednesday 10:30-12:00
I-25 Daniel Moj
Application of a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat to improve dosing regimens in adults
Wednesday 10:30-12:00
I-26 Tadakatsu Nakamura
Population Pharmacokinetic Analysis of Compound A and Its Metabolite in Healthy Subjects and Patients with Diabetic Nephropathy
Wednesday 10:30-12:00
I-27 Srividya Neelakantan
Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects with Severe Hemophilia A Across All Ages
Wednesday 10:30-12:00
I-28 Asuka Suzuki
A Bayesian approach for population pharmacokinetic modeling of alcohol in Japanese Subjects
Wednesday 10:30-12:00
I-29 Thu Thuy Nguyen
Population pharmacodynamic model of bronchodilator response to salbutamol in wheezy preschool children
Wednesday 10:30-12:00
I-30 Rikard Nordgren
Calling C functions from NONMEM
Wednesday 10:30-12:00
I-31 Ana Novakovic
A longitudinal model linking absolute lymphocyte count (ALC) and volume of T2 lesions to expanded disability status scale (EDSS) in patients with relapsing-remitting multiple sclerosis (RRMS)
Wednesday 10:30-12:00
I-32 Kayode Ogungbenro
Sparse sampling design for characterizing individual PK of recombinant factor VIII fusion protein (rFVIIIFc) in prophylactic treatment of Hemophilia A
Wednesday 10:30-12:00
I-33 Boram Ohk
Population Pharmacokinetics of Tacrolimus in Healhty Korean Subjects:role of CYP3A5 genotype and metabolite
Wednesday 10:30-12:00
I-34 Olafuyi Olusola
The Use of Physiologically Based Pharmacokinetic Modelling in Assessing Drug–drug Interactions Associated with Antimalarial Treatment in Paediatrics Co-infected with Tuberculosis: A Case Study with Lumefantrine and Rifampicin.
Wednesday 10:30-12:00
I-35 Sean Oosterholt
PKPD modelling of MYCN-inhibition in vitro and in vivo in a mouse model of neuroblastoma
Wednesday 10:30-12:00
I-36 - -
Investigation of Bayesian inference in predicting tissue concentrations using RStan
Wednesday 10:30-12:00
I-37 Maria Panselina
Dose-saturable model for amoxicillin used to predict probability of response in normal and obese pediatrics
Wednesday 10:30-12:00
I-38 Sang-In Park
Population pharmacokinetic analysis of evogliptin in subjects with varying degrees of renal function
Wednesday 10:30-12:00
I-39 Zinnia Parra-Guillen
Exploring the impact of study design on unperturbed tumour growth inhibition modelling
Wednesday 10:30-12:00
I-40 Christophe Passot
In-depth assessment of the influence of anti-drug antibodies on adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis
Wednesday 10:30-12:00
I-41 Dimple Patel
Informing modeling and clinical trial simulation using the real world data: data content, quality and availability assessment
Wednesday 10:30-12:00
I-42 Dimitrios Patsatzis
Construction and evaluation of "global" Micahelis-Menten reduced models
Wednesday 10:30-12:00
I-43 Sophie Peigné
How to handle non-linearity in absorption: a case study in oncology
Wednesday 10:30-12:00
I-44 Nathalie Perdaems
Multi-species translational PK/PD modelling in type 2 diabetes
Wednesday 10:30-12:00
I-45 Belén Pérez Solans
Modelling tumour growth and progression free survival of breast cancer patients treated with neoadjuvant therapy
Wednesday 10:30-12:00
I-46 Jonás Samuel Pérez-Blanco
Population PK and exposure-response analysis of sleep parameters for JNJ-42847922, a novel Orexin 2 receptor antagonist
Wednesday 10:30-12:00
I-47 Carlos Perez-Ruixo
Identifying lack of adherence to antipsychotic treatment using plasma concentrations measurements
Wednesday 10:30-12:00
I-48 Chiara Piana
A model-based approach to extrapolate drug-drug interactions from rats to humans
Wednesday 10:30-12:00
I-49 Philippe Pierrillas
Application of Model-Based Adaptive Optimal Design to determine a recommended dosing regimen for combination therapy in oncology
Wednesday 10:30-12:00
I-50 Nikhil Pillai
Estimating Nonlinear Dynamic Systems in Pharmacology using Chaos Synchronization
Wednesday 10:30-12:00
I-51 Italo Poggesi
A Shiny App for the Probability of Technical Success of a New Molecular Entity in the Preclinical to Clinical Translational Phase
Wednesday 10:30-12:00
I-52 Sebastian Polak
Physiologically based pharmacokinetic model (PBPK) for the halofantrine cardiac effect prediction – proof of concept study towards the system for the antimalarial drugs cardiac safety assessment.
Wednesday 10:30-12:00
I-53 Manuel Prado-Velasco
PBPK versus PK modeling of Tacrolimus drug in patients with renal transplant as knowledge engines for personalized posology software: PhysPK® development and preliminary results
Wednesday 10:30-12:00
I-54 Tim Preijers
Population pharmacokinetic analysis of perioperative factor IX dosing in hemophilia B
Wednesday 10:30-12:00
I-55 Angelica Quartino
Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3
Wednesday 10:30-12:00
I-56 Christian Hove Claussen
PharmTeX: a LaTeX-based open-source platform for automated reporting workflow
Wednesday 10:30-12:00
I-57 Theo Reijmers
Population PK Modeling of Dapivirine released from Vaginal Rings
Wednesday 10:30-12:00
I-58 Didier Renard
Label extension for canakinumab in Adult Onset Still’s Disease (AOSD) – Extrapolation from pediatrics to adults
Wednesday 10:30-12:00
I-59 Christer Rimmler
Development of a PBPK model to predict the pharmacokinetics of cefuroxime during surgery
Wednesday 10:30-12:00
I-60 Christelle Rodrigues
Population pharmacokinetics of the sustained-release granule formulation of valproic acid in epileptic children
Wednesday 10:30-12:00
I-61 Amin Rostami
Predicting diclofenac systemic and synovial fluid concentrations after dermal application using the Multi-Phase Multi-Layer MechDermA PBPK model
Wednesday 10:30-12:00
I-62 Hauke Ruehs
Exposure-response analysis of vilaprisan describing uterine fibroid size by population PK/PD modelling
Wednesday 10:30-12:00
I-63 Leire Ruiz Cerdá
Modeling of Interferon effector pathway after viral infection
Wednesday 10:30-12:00
I-64 Alberto Russu
Dose-conversion factors for risperidone and paliperidone formulations based on steady-state PK similarity
Wednesday 10:30-12:00
I-65 Sunae Ryu
Population pharmacokinetic model of propranolol and its metabolite reflecting the first-pass effect in patients with hepatic impairment
Wednesday 10:30-12:00
I-66 Muhammad Waqas Sadiq
A model-based comparison of absorption pharmacokinetics for a selective glucocorticoid receptor modulator administered with different inhalation devices
Wednesday 10:30-12:00
I-68 Mark Sale
Application of global search methods for parameter estimation in models with poorly defined objective function surfaces
Wednesday 10:30-12:00
I-69 Franziska Schädeli Stark
Assessing the adequacy of a minimal PK sampling schedule for individual dose adjustment decisions in a proof of mechanism (PoM) study in a special population
Wednesday 10:30-12:00
I-70 Stein Schalkwijk
Placental Transfer of Darunavir and Simulation of Fetal Exposure
Wednesday 10:30-12:00